Prognostic markers in lentigo maligna patients treated with imiquimod cream: A long-term follow-up study - 18/12/15
Abstract |
Background |
More data are needed to define factors that predict long-term success after imiquimod therapy for lentigo maligna (LM).
Objective |
We sought to determine the demographic, clinical, and histologic prognostic markers of relapse-free survival in patients with LM who were treated with imiquimod.
Methods |
This was a single-arm, open-label, nonrandomized, prospective study.
Results |
Eighty-nine patients with histologically confirmed LM and a median follow-up time of 4.8 years after imiquimod treatment were included in our study. Sixteen patients (18%) relapsed. Statistically significant indicators of an increased risk of local recurrence included: the total number of melanocytes, the number of basal and suprabasal melanocytes and the number of pagetoid spreading melanocytes.
Limitations |
Our study was a single-center, nonrandomized study.
Conclusion |
An assessment of different melanocyte fractions in the diagnostic baseline biopsy specimen may help to predict the response of LM to imiquimod therapy.
Le texte complet de cet article est disponible en PDF.Key words : efficacy, follow-up, imiquimod, lentigo maligna, prognostic marker, recurrence, topical immunomodulators
Plan
Dr Gautschi and Dr Oberholzer contributed equally to this study. |
|
Funding sources: None. |
|
Conflicts of interest: None declared. |
Vol 74 - N° 1
P. 81 - janvier 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?